secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spero Therapeutics, Inc. (SPRO)
CIK:        0001701108
Form:       8-K
Filed at:   2026-08-12T20:09:26+00:00
Accession:  0001193125-26-346855
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spero Q2 net loss widens to $9.6M; FDA approves Utebzi, $105M financing extends runway
--------------------------------------------------------------------------------

- Net loss of $9.6M ($0.16 diluted EPS) vs $1.7M loss ($0.03) in Q2 2025.
- No revenue in Q2 2026 vs $14.2M in Q2 2025; all deferred revenue previously recognized.
- Cash $50.8M at June 30, 2026; plus $105M royalty financing extends runway into H2 2029.
- FDA approved Utebzi (tebipenem pivoxil) for cUTIs in June 2026; GSK launch expected by end of 2026.
- Exclusive license with Innovent for SP001 (anti-CD40L) worldwide ex-Greater China; Phase 2 in IgG4-RD planned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/0001193125-26-346855-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701108/000119312526346855/d69249d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-346855

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer